|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM347596479 |
| 003 |
DE-627 |
| 005 |
20250303233358.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109163
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1158.xml
|
| 035 |
|
|
|a (DE-627)NLM347596479
|
| 035 |
|
|
|a (NLM)36244669
|
| 035 |
|
|
|a (PII)S1521-6616(22)00244-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Li, Song
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Pyroptosis predicts immunotherapy outcomes across multiple cancer types
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.11.2022
|
| 500 |
|
|
|a Date Revised 26.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Pyroptosis is a programmed cell death characterized by inflammation and may coordinate with cancer immunotherapy, but assessments of pyroptosis in patients with immunotherapy are lacking. We evaluated the pyroptosis potentials in 71 cohorts with 24,388 cancer patients. They were elevated in tumors compared to normal tissues but had a weak relationship with prognosis. High pyroptosis potentials indicated "hot tumors" characteristics and high objective response rates to PD1/PDL1 inhibitors derived from clinical trials. In 15 cohorts with patients treated with immunotherapy, a pyroptosis score showed predictive values in objective response rate, progression-free survival, and overall survival. Systematic treatments, such as chemotherapy or endocrine therapy, enhanced pyroptosis in drug-resistant tumors. These results were further validated in three independent clinical cohorts and our two institutional cohorts by immunohistochemistry. Our findings uncover a value of pyroptosis potentials to predict immunotherapy responses and a theoretical rationale for combining pyroptosis inducers and immunotherapy in cancer treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Biomarker
|
| 650 |
|
4 |
|a Immune checkpoints
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a Pyroptosis
|
| 650 |
|
4 |
|a Tumor microenvironment
|
| 700 |
1 |
|
|a Chen, Pengxiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Bo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Yuchen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Qian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Miao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dai, Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Kai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Lin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Yufeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Lian
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 245(2022) vom: 30. Dez., Seite 109163
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:245
|g year:2022
|g day:30
|g month:12
|g pages:109163
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109163
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 245
|j 2022
|b 30
|c 12
|h 109163
|